HEALTH DATA RESEARCH UK

• ◆

  3 PSCs ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +30%

  £11,124,000 → £14,461,000

• Cash

  +148.7%

  £8,502,000 → £21,143,000

• Net assets

  -13.8%

  £79,737,000 → £68,709,000

• Employees

  +24.7%

  97 → 121

• Operating profit

  -74.6%

  -£6,316,000 → -£11,028,000

• Profit before tax

  -74.6%

  -£6,316,000 → -£11,028,000

• Wages

  +25.7%

  £6,052,000 → £7,610,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Auditor

HaysMac LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“HDR UK has committed core funding in place to cover its activities until 31 March 2028 a grant agreement from the Medical Research Council to HDR UK for £71.3m was signed 5th April 2023. The Trustees have therefore been able to satisfy themselves that the Company is able to continue as a going concern.”

Significant events

• “In July 2024 a new study, enabled by the BHF Data Science Centre and led by the Universities of Cambridge, Bristol and Edinburgh, showed that the incidence of cardiovascular events - such as heart attacks and strokes - was lower after COVID-19 vaccination than before or without vaccination.”
• “August 2024 saw a new announcement from one of the three major research streams of global dementia research initiative NEURii, a collaboration between HDR UK, industry partners and academic institutions which started in 2023.”
• “HDR UK brought in the Autumn with the signing of a landmark Memorandum of Understanding (MoU) with the National Research Foundation Singapore (NRF).”
• “In November 2024, researchers published a paper in BMJ Medicine shedding new light on the combination of chronic health conditions which add to NHS winter pressures.”
• “We also launched the Uniting the UK's Health Data: A Huge Opportunity for Society, known as the Sudlow Review - an independent review into the current health data science landscape.”
• “In April 2025, the Government announced it would introduce a Health Data Research Service.”
• “HDR UK started 2025 with a bang, launching its first ever impact report at its inaugural lecture bringing together senior figures across health and science.”
• “In July 2024, HDR UK launched the Dementia Trials Accelerator (DTA) in partnership with the UK Dementia Research Institute (UK DRI) with funding of £20m from the Medical Research Council (MRC).”
• “In the same month, HDR UK and Dementia Platform UK (DPUK), in partnership with UK DRI and the Motor Neurone Disease (MND) research community, launched the MND Research Data Catalyst (MND-RDC).”
• “Finally, the newest addition to the Brain Health portfolio was a UK-wide study announced in March 2025, an innovative dementia research initiative to be delivered in collaboration with GSK, HDR UK, and the UK DRI over the next 3-4 years.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.